SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-010093
Filing Date
2024-02-02
Accepted
2024-02-02 07:53:44
Documents
13
Period of Report
2024-01-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20240130.htm   iXBRL 8-K 43734
2 EX-99.1 sabs-ex99_1.htm EX-99.1 12915
  Complete submission text file 0000950170-24-010093.txt   208154

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240130.xsd EX-101.SCH 45415
14 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240130_htm.xml XML 6415
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 24588830
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)